

02nd August, 2018

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,


Sub.: Presentation to analysts on un-audited Consolidated Financial Results for the quarter ended 30th June, 2018

The presentation on un-audited Consolidated Financial Results for the quarter ended 30th June, 2018 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: As above



Q1 FY 2018-19



Consolidated Revenues for Q1 2018-19

(₹ Crore)

Particulars	Q1 1819	Q1 1718	Gr%
India	830	464	79%
US	334	272	23%
Brazil	169	181	-7%
Germany	251	190	32%
Other	168	126	34%
Others (Incl contract Mfg.)	120	129	-7%
Total	1,872	1,362	37%

